The low immunisation rate reported highlights the difficulties of reaching young adult women.

Similar to other European countries, cervical infection with HPV-16, the HPV type with the strongest oncogenic potential, were most common both overall and among women with cervical disease.

The paper provides and interesting review of the introduction of HPV vaccines in the Nordic countries.

Today, ECDC publishes an update to its 2008 Guidance on human papillomavirus (HPV) vaccines in Europe. The update follows the introduction of vaccination programmes in 19 European countries and new evidence from research studies over the past four years.